New data now show that perioperative systemic therapy with apalutamide can improve outcomes after radical prostatectomy.

In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.

Surgeons’ hands-on successes and innovators like Laënnec and John Hunter shifted authority from texts to corpses, instruments ...

Data from the long-running HOME study links higher exposure to certain polyfluoroalkyl substances ‘forever chemicals’ with ...

Backed by 26 ministries and GRADE evidence, PAHO's new clinical pathway could accelerate access to SGLT2 inhibitors and ...

Join Drs Steven Feldman and Jonathan Kay as they examine the data on safety, switching, and confidence in psoriasis ...

A survey found that clinicians are not discussing genetic testing with 80% of patients with kidney disease who meet ...

The largest randomized trial of its kind to date found noninferior survival and better arm morbidity among patients with breast cancer who did not undergo completion axillary lymph node dissection.

A higher intake of several food colouring additives is associated with an increased risk of developing type 2 diabetes, an ...

From narrow volume windows to SGLT2 inhibitors and emerging devices, Drs Kevin Alexander and Sarah Cuddy discuss heart ...